Business context and reporting period
The supplied filing is Frequency Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2020, filed November 16, 2020. This does not match the request metadata identifying Korro Bio, Inc.; verify the issuer before relying on this summary.
Frequency is a clinical-stage biotechnology company developing FX-322 for sensorineural hearing loss (SNHL) using its progenitor cell activation platform, and pursuing a multiple sclerosis program. It has no approved products and has generated no product-sales revenue. Unless otherwise indicated, amounts below are in U.S. dollars and millions.
Financial performance and position
- Third quarter: Revenue was $11.2 million, versus $24.2 million in Q3 2019; operating expenses were $16.7 million versus $25.5 million; operating loss was $5.4 million versus $1.3 million; and net loss was $5.3 million versus $0.6 million. Basic and diluted loss per share was $0.16 versus $0.73.
- Nine months: Revenue was $27.0 million versus $24.2 million in 2019; operating expenses were $44.3 million versus $38.4 million; operating loss was $17.3 million versus $14.2 million; and net loss was $16.3 million versus $13.3 million. Loss per share was $0.51 versus $7.17.
- Revenue quality: Revenue principally reflects recognition over time of the $80 million Astellas upfront collaboration payment, not product sales. The company had recognized $55.9 million of that payment through September 30, 2020. The filing states that revenue from the collaboration is recognized as the FX-322 Phase 2a work is performed.
- Costs and margins: R&D expense rose 94% to $25.6 million for the nine months, primarily from increased personnel, outsourced research, and FX-322 development. G&A rose 90% to $18.7 million, including higher personnel, stock compensation, directors’ and officers’ insurance, and public-relations costs. Operating margins are not a useful indicator of product economics because the company is pre-commercial and collaboration revenue is recognized over time.
- Cash flow: Operating activities used $30.4 million in the first nine months of 2020, compared with $64.0 million provided in 2019. The change was driven in part by a $27.0 million decrease in deferred revenue in 2020; 2019 cash flow included substantial collaboration-related deferred revenue and royalty-payable movements. Investing activities provided $14.8 million, mainly from securities redemptions, and financing activities provided $41.3 million, principally from the July private placement.
- Liquidity and capital: At September 30, cash and cash equivalents were $224.2 million, restricted cash was $1.8 million, and current assets totaled $227.3 million against current liabilities of $32.9 million. Stockholders’ equity was $199.6 million and accumulated deficit was $85.2 million. No borrowings are reported on the balance sheet. The July 2020 private placement raised $40.1 million net from 2.35 million shares sold at $18 per share.
- Lease obligations: The company reported $2.2 million in operating lease liabilities on its balance sheet. Aggregate future minimum lease payments, including the Lexington facility, were $49.3 million, largely reflecting the planned 10-year Lexington lease with approximately $47 million of payments.
Material changes versus the prior comparable period
- Q3 revenue declined by $13.0 million year over year, while nine-month revenue increased by $2.8 million. The comparisons are affected by the timing of Astellas revenue recognition and by $16.0 million of 2019 revenue recognized in an amount corresponding to the MIT sublicense royalty expense.
- Q3 operating loss widened by $4.2 million and nine-month operating loss widened by $3.1 million, as R&D and G&A spending increased. The absence of the $16.0 million royalty expense recorded in Q3 2019 partly offset the higher operating costs in the 2020 comparison.
- Cash and cash equivalents increased from $200.2 million at December 31, 2019 to $224.2 million at September 30, 2020, supported chiefly by the private placement; operating cash use offset some of the proceeds.
- The company adopted lease accounting standard ASC 842 in January 2020, recording right-of-use assets and lease liabilities. Prior-period balance sheets were not restated, limiting comparability.
Outlook, management commentary, risks, and unusual items
- Management reported completion of enrollment of 95 patients in the FX-322 Phase 2a trial in September 2020. It planned to report day-90 data in late Q1 2021 and 210-day data in late Q2 2021. These are forward-looking plans, not reported results.
- After quarter-end, the company commenced a Phase 1b study of FX-322 for age-related hearing loss in October 2020, with results expected in Q2 2021. It planned a separate Phase 1b study in severe SNHL for Q4 2020, with results expected in Q3 2021. It also intended to submit an IND or foreign equivalent for its MS candidate in the second half of 2021.
- Management’s MD&A says existing cash, cash equivalents, and short-term investments were expected to fund operations into 2023. Separately, the financial-statement liquidity note says resources were expected to fund planned operations for at least 12 months from when the statements were available to be issued. Investors should reconcile these different runway statements and the assumptions behind them.
- The company expects operating losses and R&D and G&A expenses to continue increasing. It may need additional financing; financing may be unavailable or require dilution, restrictive terms, or surrender of valuable rights. There is no assurance it will reach profitability.
- COVID-19 had previously interrupted enrollment at some trial sites and constrained research-site activity. The company reported that most employees were working remotely and that its Farmington site had resumed at reduced capacity. Further disruptions could affect trials, suppliers, operations, financing access, and timelines.
- Key risks include FX-322 clinical and regulatory failure, uncertainty around the novel progenitor-cell-activation approach, reliance on third-party manufacturers and CROs, dependence on Astellas for development and commercialization outside the U.S., and the need to maintain licensed intellectual property rights. The filing identifies reliance on a single clinical-trial manufacturer as a supply risk.
- The Astellas agreement provides for up to $230 million in development milestones, up to $315 million in commercial milestones, and tiered royalties; these amounts are contingent and are not assured future revenue. Astellas may terminate the agreement at will on 60 days’ notice.
- The company signed a letter of intent during Q3 to terminate its Woburn lease and expected the Lexington lease to commence in December 2020. The filing reports no material legal proceedings and states disclosure controls were effective as of September 30, 2020.
Most important facts for an investor to verify
- Confirm the filing’s issuer: the document is for Frequency Therapeutics, not Korro Bio.
- Review the underlying Astellas agreement, remaining deferred revenue, revenue-recognition assumptions, milestone conditions, and termination rights.
- Reconcile the stated cash runway into 2023 with the separate “at least 12 months” liquidity statement, and assess the expected cash burn and financing needs.
- Check the status and final results of FX-322 trials against the timelines stated in this 2020 filing; the reported early and exploratory findings are not proof of later-stage efficacy or approval.
- Assess the Lexington and Woburn lease commitments, including the Woburn termination letter of intent and the approximately $49.3 million of future minimum lease payments disclosed.